ORPHAZYME A/SORPHAZYME A/SORPHAZYME A/S

ORPHAZYME A/S

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪32.59 M‬DKK
−737.7DKK
‪−26.05 M‬DKK
‪25.82 K‬
Beta (1Y)
0.18

About ORPHAZYME A/S

CEO
Jakob Færch Bendtsen
Headquarters
Copenhagen
Employees (FY)
1
Founded
2009
ISIN
DK0062502894
FIGI
BBG00J25X0C4
Orphazyme A/S is a biopharmaceutical company, which engages in the research and development of treatments for rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ORPHA is 976.0 DKK — it has increased by 0.10% in the past 24 hours. Watch ORPHAZYME A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXCOP exchange ORPHAZYME A/S stocks are traded under the ticker ORPHA.
ORPHA stock has fallen by 2.19% compared to the previous week, the month change is a 2.44% fall, over the last year ORPHAZYME A/S has showed a 44.36% decrease.
ORPHA reached its all-time high on Feb 13, 2020 with the price of 137500.0 DKK, and its all-time low was 407.0 DKK and was reached on Dec 8, 2023. View more price dynamics on ORPHA chart.
See other stocks reaching their highest and lowest prices.
ORPHA stock is 1.55% volatile and has beta coefficient of 0.18. Track ORPHAZYME A/S stock price on the chart and check out the list of the most volatile stocks — is ORPHAZYME A/S there?
Today ORPHAZYME A/S has the market capitalization of ‪34.43 M‬, it has decreased by 3.05% over the last week.
Yes, you can track ORPHAZYME A/S financials in yearly and quarterly reports right on TradingView.
ORPHAZYME A/S is going to release the next earnings report on Aug 27, 2024. Keep track of upcoming events with our Earnings Calendar.
ORPHA net income for the last half-year is ‪−13.26 M‬ DKK, while the previous report showed ‪−12.78 M‬ DKK of net income which accounts for −3.75% change. Track more ORPHAZYME A/S financial stats to get the full picture.
No, ORPHA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 19, 2024, the company has 1.00 employees. See our rating of the largest employees — is ORPHAZYME A/S on this list?
Like other stocks, ORPHA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ORPHAZYME A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ORPHAZYME A/S technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ORPHAZYME A/S stock shows the sell signal. See more of ORPHAZYME A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.